Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The role of CD4 T cells in tumor-specific CD8 T cell reprogramming [RNA-Seq]

ABSTRACT: RNA-seq analysis of tumor-specific CD8 T cells from tumors with and without tumor-specific CD4 T cells

ORGANISM(S): Mus musculus

PROVIDER: GSE265846 | GEO | 2024/05/19

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

The role of CD4 T cells in tumor-specific CD8 T cell reprogramming [ATAC-Seq]

Project description:ATAC-seq analysis of tumor-specific CD8 T cells from tumors with and without tumor-specific CD4 T cells

2024-05-19 | GSE265847 | GEO

The role of CD4 T cells in tumor-specific CD8 T cell reprogramming [RNA-Seq]

Project description:The role of CD4 T cells in tumor-specific CD8 T cell reprogramming [RNA-Seq]

| PRJNA1104533 | ENA

The role of CD4 T cells in tumor-specific CD8 T cell reprogramming [ATAC-Seq]

Project description:The role of CD4 T cells in tumor-specific CD8 T cell reprogramming [ATAC-Seq]

| PRJNA1104535 | ENA

Tumor-specific CD8+ T cells

Project description:Tumor-specific CD8+ T cells

| PRJNA949608 | ENA

Tumor-specific CD4+ T cells eradicate established melanoma

Project description:Adoptive transfer of CD4+ T cells (TRP-1 CD4+ T cells) specific for tyrp-1 (tyrosinase-related protein 1) eradicate established tumors (melanoma) in lymphopenic RAG-/- hosts. In vitro differentiated CD8+ T cells have been the primary focus of immunotherapy of cancer with little focus on CD4+ T cells. Immunotherapy involving in vitro differentiated T cells given after lymphodepleting regimens significantly augments antitumor immunity in animals and human patients with cancer. However, the mechanisms by which lymphopenia augments adoptive cell therapy and the means of properly differentiating T cells in vitro are still emerging. We demonstrate that naïve tumor/self-specific CD4+ T cells naturally differentiated into T helper type 1 (Th1) cytotoxic T cells in vivo and caused the regression of established tumors and depigmentation in lymphopenic hosts. Therapy was independent of vaccination, exogenous cytokine support, CD8+-, B-, NK and NK-T cells. Proper activation of CD4+ T cells in vivo was important for tumor clearance as naïve tumor-specific CD4+ T cells could not completely treat tumor in lymphopenic common gamma chain-deficient (gc-/-) hosts. gc signaling in the tumor-bearing host was important for survival and proper differentiation of adoptively transferred tumor-specific CD4+ T cells. Thus, these data provide a platform for designing immunotherapies that incorporate tumor/self-reactive CD4+ T cells. 2 x 10^5 sorted TRP-1 CD4+ T cells were transferred i.v. into tumor-bearing RAG-/- hosts on day 7-10 after tumor challenge, and ~1 x 10^6 CD4+ T cells were isolated 1 week later by flow sorting from pooled lymph nodes (LN) or spleens. Dye-swaps were performed.

2010-01-14 | E-GEOD-19904 | biostudies-arrayexpress

Tumor-specific CD4+ T cells eradicate established melanoma

2010-01-15 | GSE19904 | GEO

Whole mouse genome analysis of LCMV-specific CD4 and CD8 T cells throughout acute and chronic LCMV infection.

Project description:CD4 and CD8 T cells display functional defects during chronic infection such as loss of certain cytokines. Recent studies have suggested that CD4 T cells may actually gain other functions, however. Here, we analyzed gene expression profiles from LCMV-specific CD4 and CD8 T cells throughout the response to either acute LCMV or chronic LCMV infection. This alllowed us to identify CD4-specific changes during chronic infection compared to acute infection but also revealed shared core regulators between CD4 and CD8 T cells. LCMV-specific CD4 and CD8 T cells were isolated 6, 8, 15 and 30 days post infection with LCMV Armstrong or LCMV clone 13. Naïve CD4 and CD8 T cells were also isolated from naïve mice as comparisons. Four replicates of each sample were hybridized. The only exception is LCMV-specific CD4 T cells isolated 6 days post infection with LCMV-Arm where only three replicates were hybridized.

2012-12-12 | E-GEOD-30431 | biostudies-arrayexpress

Anti-CD4 treatment increases tumor-suppressive IL18Rαhi CD8+ T cells

Project description:Anti-CD4 monoclonal antibody, a prominent immunomodulatory agent, elicits robust anti-tumor immunity in various cancers by increasing tumor-infiltrating lymphocytes and promoting CD8+ T cell reactivity against tumor cell-derived antigens. We conducted single-cell transcriptome analysis of anti-CD4-exposed lymphoid cells to investigate the detailed mechanism.

2021-07-30 | GSE180991 | GEO

RNA-seq of tumor-specific CD8+ T cells

Project description:RNA-seq of tumor-specific CD8+ T cells

| PRJNA949616 | ENA

scRNA-seq of tumor-specific CD8+ T cells

Project description:scRNA-seq of tumor-specific CD8+ T cells

| PRJNA949613 | ENA